| First Author | Ruby CE | Year | 2007 |
| Journal | Eur J Immunol | Volume | 37 |
| Issue | 1 | Pages | 157-66 |
| PubMed ID | 17183611 | Mgi Jnum | J:117051 |
| Mgi Id | MGI:3695516 | Doi | 10.1002/eji.200636428 |
| Citation | Ruby CE, et al. (2007) Anti-OX40 stimulation in vivo enhances CD8(+) memory T cell survival and significantly increases recall responses. Eur J Immunol 37(1):157-66 |
| abstractText | There is growing evidence that engagement of OX40 (CD134), a member of the TNF receptor superfamily, can directly stimulate antigen-specific CD8(+) T cells. It has been shown that CD8(+) T cells express OX40 following activation, but the response of antigen-specific CD8(+) T cells to OX40 stimulation has not been fully characterized. We utilized an antigen-specific transgenic CD8(+) T cell model (OT-I) to determine if OX40 engagement can boost the generation of antigen-specific CD8(+) T cell memory. Our results demonstrate that enhanced OX40 costimulation, via an agonist anti-OX40 antibody, increases CD25 and phospho-Akt expression on the antigen-specific CD8(+) T cells and significantly increases the generation of long-lived antigen-specific CD8(+) memory T cells. The increased numbers of memory CD8(+) T cells generated via anti-OX40 treatment still required the presence of CD4(+) T cells for their long-term maintenance in vivo. In addition, anti-OX40 costimulation greatly enhanced antigen-specific CD8(+) T cell recall responses. These data show that OX40 engagement in vivo increases the number of antigen-specific CD8(+) memory T cells surviving after antigen challenge and has implications for the development of more potent vaccines against pathogens and cancer. |
